JPMorgan Chase & Co. Boosts Stock Position in Embecta Corp. $EMBC

JPMorgan Chase & Co. lifted its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 39.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 434,822 shares of the company’s stock after buying an additional 123,113 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.73% of Embecta worth $6,135,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Jefferies Financial Group Inc. raised its position in Embecta by 40.4% during the third quarter. Jefferies Financial Group Inc. now owns 1,884,875 shares of the company’s stock worth $26,596,000 after acquiring an additional 542,162 shares during the period. Exchange Traded Concepts LLC lifted its holdings in Embecta by 519.2% during the third quarter. Exchange Traded Concepts LLC now owns 124,429 shares of the company’s stock valued at $1,756,000 after purchasing an additional 104,334 shares in the last quarter. Public Sector Pension Investment Board grew its position in shares of Embecta by 57.7% in the third quarter. Public Sector Pension Investment Board now owns 314,129 shares of the company’s stock valued at $4,432,000 after purchasing an additional 114,902 shares during the period. Teacher Retirement System of Texas grew its position in shares of Embecta by 365.7% in the third quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock valued at $5,255,000 after purchasing an additional 292,477 shares during the period. Finally, Squarepoint Ops LLC increased its stake in shares of Embecta by 103.6% during the second quarter. Squarepoint Ops LLC now owns 403,412 shares of the company’s stock worth $3,909,000 after purchasing an additional 205,311 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Price Performance

Shares of NASDAQ EMBC opened at $8.84 on Wednesday. The firm has a 50-day simple moving average of $9.93 and a 200-day simple moving average of $12.06. The stock has a market capitalization of $523.50 million, a price-to-earnings ratio of 3.73 and a beta of 1.10. Embecta Corp. has a 52 week low of $8.47 and a 52 week high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The firm had revenue of $261.20 million for the quarter, compared to analyst estimates of $258.07 million. During the same period in the previous year, the business posted $0.65 earnings per share. Embecta’s quarterly revenue was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, equities research analysts expect that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th were issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 6.8%. The ex-dividend date was Friday, February 27th. Embecta’s payout ratio is currently 25.32%.

Analyst Ratings Changes

A number of brokerages recently weighed in on EMBC. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price target on shares of Embecta in a research note on Friday, February 6th. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $18.50.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.